Recent News
New Haven, CT, November 30, 2020 – Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies […] Read More...
Watch the Video to Learn More
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates in oncology and infectious disease
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates in oncology and infectious disease
Our Sciences
News
By Alexander Soule Updated 8:10 am EST, Friday, November 13, 2020 Photo: Tyler Sizemore / Hearst Connecticut Media A nurse […] Read More
New Haven, CT, November 9, 2020 – Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to […] Read More
New Haven, CT, October 29, 2020 – Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to […] Read More
NEW HAVEN, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) — Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific […] Read More
Events
